Kirschbaum, M. H., Frankel, P., Synold, T. W., Xie, Z., Yen, Y., Popplewell, L., . . . Newman, E. M. (2016). A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide Against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study. Leuk Lymphoma.
Chicago Style CitationKirschbaum, Mark H., et al. "A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide Against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study." Leuk Lymphoma 2016.
Cita MLAKirschbaum, Mark H., et al. "A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide Against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study." Leuk Lymphoma 2016.